Follow us on Twitter
twitter icon@FreshPatents


Immunotherapy patents

      

This page is updated frequently with new Immunotherapy-related patent applications.




 Expansion of lymphocytes with a cytokine composition for active cellular immunotherapy patent thumbnailExpansion of lymphocytes with a cytokine composition for active cellular immunotherapy
The present invention relates to a composition for expanding lymphocytes comprising at least two types of cytokines selected from interleukin 2 (il-2), interleukin 15 (il-15) and interleukin 21 (il-21). It further relates to a method of preparing a population of clinically relevant lymphocytes, comprising the steps of: obtaining a body sample from a mammal in particular a tissue sample or body liquid sample, comprising at least one lymphocyte and optionally separating the cells in the body sample, culturing the body sample in-vitro to expand and/or stimulate lymphocytes in the sample wherein the culturing comprises using il-2, il-15 and/or il-21, and optionally determining the presence of clinically relevant lymphocyte in the cultured sample.
Polybiocept Ab


 Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring patent thumbnailMethods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring
Described herein are methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring based on the level of tigit, flg2 and/or il-33 expression and/or activity. In some embodiments, the methods and compositions described herein are directed to treatment and/or therapy monitoring of cancer and/or infections (e.g., chronic viral infection, intracellular and/or extracellular bacterial infection, and/or fungal infection).
The Brigham And Women's Hospital, Inc.


 Met e 1 tropomyosin variants for use in allergen-specific immunotherapy patent thumbnailMet e 1 tropomyosin variants for use in allergen-specific immunotherapy
The present invention provides isolated met e 1 polypeptides and nucleic acids encoding the isolated polypeptides that can prevent and/or alleviate an allergic response to shellfish tropomyosin. The polypeptides are based on the shrimp tropomyosin met e 1 protein and have been modified to act as hypoallergens.
The Regents Of The University Of California


 Multidentate bifunctional chelating agents for radionuclide complexation in diagnostics and therapy patent thumbnailMultidentate bifunctional chelating agents for radionuclide complexation in diagnostics and therapy
The invention relates to octadentate ligands of a general formula r1-d-x-d-x-d-x-d-e-r2, wherein d is c(o)n(oh) or n(oh)c(o), pyrimidinone or pyridinone, each x independently of any other x is a saturated or partially unsaturated, substituted or unsubstituted linker comprising 8-11 atoms selected from any of n, c, o; r1 is alkyl, cycloalkyl, arene, or heteroarene, e is a saturated or partially unsaturated, substituted or unsubstituted chain comprising 1-50 atoms and r2 is a moiety capable of selectively binding to a biomolecule, or a nanoparticle. The invention further relates to complexes of the ligand, particularly radionuclides and their use in radioimmunotherapy and imaging..
Universitatsspital Basel


 Biomarker directed multi-target immunotherapy patent thumbnailBiomarker directed multi-target immunotherapy
This invention provides methods and compositions for using evaluating biomarker expression in a disease and providing a multi-targeted listeria-based immunotherapeutic approach against said disease. In a related aspect, the invention relates to a method of treating a disease in a subject, the method comprising the steps of: a.
Advaxis, Inc.


 Multi-component-multistage malaria vaccines patent thumbnailMulti-component-multistage malaria vaccines
The present disclosure relates to novel malaria vaccines composed of different recombinant proteins, in particular recombinant fusion proteins comprising several different plasmodium falciparum antigens from the pre-erythrocytic the blood, and the sexual parasite stages. The proteins and/or fusion proteins will be used in a mixture vaccine formulation to elicit protective immune responses in humans.
Fraunhofer-gesellschaft Zur Foerderung Der Angewandten Forschung E.v.


 Oral composition and methods for immunotherapy patent thumbnailOral composition and methods for immunotherapy
A composition includes a metal chemically bound to at least one heat-denatured tumor antigen and at least one heat-denatured alloantigen. The tumor antigen and/or the alloantigen are hydrolyzed.

 Combinatorial immunotherapy for pancreatic cancer treatment patent thumbnailCombinatorial immunotherapy for pancreatic cancer treatment
The invention features compositions and methods for treating and preventing pancreatic cancer.. .
The Johns Hopkins University


 Combination of cd95/cd95l inhibition and cancer immunotherapy patent thumbnailCombination of cd95/cd95l inhibition and cancer immunotherapy
The present invention relates to the treatment of cancer using a combination of an inhibitor of the cd95/cd95l signaling system and an immunotherapeutic agent, e.g. A cancer vaccine or a checkpoint inhibitor.
Apogenix Ag


 Methods of enhancing t-cell longevity and uses thereof patent thumbnailMethods of enhancing t-cell longevity and uses thereof
The present disclosure encompasses methods of enhancing t cell longevity and/or t cell function by promoting mitochondrial fusion and/or mitochondrial structural remodeling including cristae. Compositions comprising the enhanced t cells may be used in adoptive cellular immunotherapy..
Washington University


Treatment of glioma by anti-angiogenic active immunization for direct tumor inhibition and augmentation of chemotherapy, immunotherapy and radiotherapy efficacy

Disclosed are compositions of matter, therapeutic protocols, and immunization means to induce an active immune response to vasculature feeding glioma or other brain neoplasia. In one embodiment the invention provides administration of placental derived endothelial cells at concentrations of 10 million to 50 million administered in a manner to stimulate immunity toward blood vessels supplying glioma or other brain neoplastic malignancies.
Batu Biologics, Inc.

Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias

Methods of treating, preventing or managing leukemias are disclosed. The methods encompass the administration of an immunomodulatory compound of the invention known as revlimid® or lenalidomide.
Celgene Corporation

Monoclonal antibodies to programmed death 1 (pd-1)

The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to pd-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided.
Ono Pharmaceutical Co., Ltd.

Genetic engineering of macrophages for immunotherapy

Disclosed are methods of making a genetically modified immune cell for modifying a tumor microenvironment (tme) and methods of modifying a tumor microenvironment (tme). In some embodiments, the method can include delivering a first vector to an immune cell, wherein the first vector comprises a nucleic acid encoding a protein that induces t-cell proliferation, promotes persistence and activation of endogenous or adoptively transferred nk or t cells and/or induces production of an interleukin, an interferon, a pd-1 checkpoint binding protein, hmgb1, myd88, a cytokine or a chemokine.
Seattle Children's Hospital (dba Seattle Children' S Research Institute)

Tumor associated vaccines and compositions for disrupting tumor-derived immunosuppression for use in combination cancer immunotherapy

In one embodiment, a single modality cancer immunotherapy regimen that includes a therapeutic composition is provided. Such a therapeutic composition may include a salmonella strain comprising a plasmid that expresses an shrna molecule that suppresses the expression of an immunosuppressive target and suppresses tumor growth.
City Of Hope

Composition and diagnosis and immunotherapy of lung cancer

The present invention includes compositions and methods for the diagnosis and treatment of lung cancer with a recombinant tumor-associated antigen loaded antigen presenting cell that generates a cytotoxic t lymphocyte specific immune response to at least one of sp17, akap-4, or pttg1 expressed by one or more lung cancer cells.. .
Texas Tech University System

Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Detecting mutations for cancer screening and fetal analysis

Embodiments are related to the accurate detection of somatic mutations in the plasma (or other samples containing cell-free dna) of cancer patients and for subjects being screened for cancer. The detection of these molecular markers would be useful for the screening, detection, monitoring, management, and prognostication of cancer patients.
The Chinese University Of Hong Kong

Method of engineering multi-input signal sensitive t cell for immunotherapy

The present invention relates to a method to engineer immune cell for immunotherapy. In particular said immune cells are engineered with chimeric antigen receptors, which be activated by the combination of hypoxia and ligand extracellular binding as input signals.
Cellectis

Tumor vaccination involving a humoral immune response against self-proteins

The present invention relates to tumor immunotherapy, in particular to tumor vaccination, using chimeric proteins comprising all or a portion of a hepatitis b virus core antigen protein and an amino acid sequence comprising an epitope derived from the extracellular portion of a tumor-associated antigen. In particular, the present invention provides virus-like particles comprising said chimeric proteins, which are useful for eliciting a humoral immune response in a subject against the tumor-associated antigen, in particular against cells carrying said tumor-associated antigen on their surface, wherein the tumor-associated antigen is a self-protein in said subject..
Biontech Ag

Method for in situ inhibition of regulatory t cells

The present invention pertains to engineered t-cells, method for their preparation and their use as medicament, particularly for immunotherapy. The engineered t-cells of the invention are designed to express both a chimeric antigen receptor (car) directed against at least one antigen expressed at the surface of a malignant or infected cell, and a secreted inhibitor of regulatory t-cells (treg).
Cellectis

Brain cancer immunotherapy

The invention describes immunotherapies for treating various cancers in nervous system, particularly brain cancer. In various embodiments, the method may comprise: obtaining a tumor tissue from the subject; preparing a tumor cell lysate from the tumor tissue; isolating an immune cell from the subject; priming the immune cell against the tumor cell lysate.
University Of Southern California

Methods and compositions for neural disease immunotherapy

The invention provides antibodies to specific neural proteins and methods of using the same.. .
Genentech, Inc.

Bispecific antibody for cancer immunotherapy

Disclosed are compositions and methods for targeted treatment of tag-72-expressing cancers. In particular, bispecific antibodies are disclosed that are able to engage t-cells to destroy tag-72-expressing malignant cells.
H. Lee Moffitt Cancer Center And Research Institute, Inc.

Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Cs1 specific multi-chain chimeric antigen receptor

The present invention relates to a new generation of chimeric antigen receptors (car) referred to as multi-chain cars, which are made specific to the antigen cs1. Such cars aim to redirect immune cell specificity and reactivity toward malignant cells expressing the tumor antigen cs1.
Cellectis

Ganciclovir derivatives for modulating innate and adaptive immunity and for use in immunotherapy

Compositions and methods for modulating innate and adaptive immunity and for use in immunotherapy are disclosed. In particular, the invention relates to novel ganciclovir derivatives and methods of using them for the treatment of immune-related disorders, including inflammation, autoimmunity, and infections, and neurological disorders, and cancer..
The Board Of Trustees Of The Leland Stanford Junior University

Indoleamine 2,3-dioxygenase based immunotherapy

The use of ido and immunogenic peptide fragments hereof in cancer and infection treatment, diagnosis and prognosis is also provided.. .

Methods for off-the-shelf-tumor immunotherapy using allogeneic t-cell precursors

The inventive subject matter relates to methods for treating a t-cell deficiency in a subject in need thereof, comprising administering to said subject a t-cell precursor isolated from an allogeneic donor, provided that said allogeneic donor is not mhc-matched to said subject. The inventive methods can be further enhanced by genetic engineering for targeted immunotherapy..
Memorial Sloan-kettering Cancer Center

Method of evaluating glioblastoma multiforme patient applicable to immunotherapy treatment based on dendritic cell tumor vaccines and prognosticating survival rate in glioblastoma mulztiforme patient after treatment

A method of evaluating if a glioblastoma multiforme (gbm) patient is applicable to be treated with an immunotherapy based on dendritic cell tumor vaccines includes a sample obtaining step to obtain a sample from the gbm patient, a detecting step to detect an expression level of a biomarker, and a comparing step to compare the expression level of the biomarker to a threshold, wherein the gbm patient is applicable to treat with the immunotherapy based on dendritic cell tumor vaccines when the expression level of the biomarker is lower than the threshold. A method of prognosticating a survival rate in the gbm patient after a treatment includes a sample obtaining step, a detecting step, and a comparing step, wherein the gbm patient is determined to have a good prognosis after the treatment when the expression level of the sample from the gbm is lower than the threshold..
China Medical University Hospital

Immunotherapy with binding agents

The present invention provides agents, such as soluble receptors, antibodies, and small molecules that modulate the immune response. In some embodiments, the agents activate or increase the immune response to cancer and/or a tumor.
Oncomed Pharmaceuticals

Interleukin 15 as selectable marker for gene transfer in lymphocytes

The present invention relates to the use of interleukin-15 (il-15) as selectable marker for gene transfer, preferably of at least one gene of therapeutic interest, into a mammalian cell or cell line, in particular a human cell or cell line. The present invention furthermore relates to transgenic mammalian cells or cell lines expressing il-15 as selectable marker and co-expressing at least one protein of interest encoded by at least one gene of interest, which is preferably a protein of therapeutic interest.
Chemotherapeutisches Forschungsinstitut Georg-speyer-haus

Multi-indication mrna cancer immunotherapy

Synthetic bacterial messenger rna can be used to prepare autologous, allogenic or direct nucleic acid cancer vaccines. Cancer cells are transfected either in vitro or in vivo with mrna obtained from dna that encodes an immunogenic bacterial protein.
Morphogenesis, Inc.

Combination treatment comprising administration of 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahydropyridines

And a compound useful in active or passive tau immunotherapy, a compound useful in active or passive aβ peptide immunotherapy, an nmda receptor antagonists, an acetylcholine esterase inhibitor, an antiepileptic, an anti-inflammatory drug, a tau aggregation inhibitor or an ssri for the treatment of neurodegenerative or cognitive disorders.. .

Cd8+ regulatory t-cells for use in the treatment of inflammatory and autoimmune diseases

The present invention relates to a method for identifying cd8+ treg cells suitable for use as starting material in cellular immunotherapy, the method comprising i) analysing samples from target tissue a to identify cd8+ treg cells with migratory character between the diseased tissue, collecting lymphatics, peripheral blood, distinct tissue adjacent to the diseased target tissue a and/or distinct tissue that is not vicinal though has migratory treg communication with target tissue a, v) analysing samples from peripheral blood, tissue c, to identify cd8+ treg cells with migratory character and/or functional character where the treg cells are also emigrant from target tissue a, vi) analysing sample(s) from tissue compartments a and/or b and c, that are analytically or physically depleted of emigrants from thymus and/or immigrants from peripheral blood to a lymph node, to restrict analyses to cd8+ treg cells of target tissue a origin and/or tropism, to identify emigrant cd8+ treg cell populations of target tissue a, to identify emigrant cd8+ treg cell populations with propensity to immigrate to target tissue a, to identify a migratory and/or functional defect in the cd8+ treg cell population identified as expressing migratory and/or functional elements specific for target tissue a in any of tissue a, b or c, and whereby a combination of surface or intracellular markers on cd8+ treg cells is identified, which combination identifies which surface or intracellular markers should be present and which surface markers should not be present in cd8+ treg cell populations suitable for use as starting material in cellular immunotherapy.. .
Genovie Ab

Method for the identification of cd4+ regulatory t-cells for use in the treatment of inflammatory and autoimmune diseases

The present invention relates to a method for identifying cd4+ treg cells suitable for use as starting material in cellular immunotherapy, the method comprising i) analysing samples from target tissue a to identify cd4+ treg cells with migratory in character between the diseased tissue, collecting lymphatics, peripheral blood, distinct tissue adjacent to the diseased target tissue a and/or distinct tissue that is not vicinal though has migratory treg communication with target tissue a, v) analysing samples from peripheral blood, tissue c, to identify cd4+ treg cells with migratory character and/or functional character where the treg cells are also emigrant from target tissue a, vi) analysing sample(s) from tissue compartments a and/or b and c, that are analytically or physically depleted of emigrants from thymus and/or immigrants from peripheral blood to a lymph node, to restrict analyses to cd4+ treg cells of target tissue a origin and/or tropism, to identify emigrant cd4+ treg cell populations of target tissue a, to identify emigrant cd4+ treg cell populations with propensity to immigrate to target tissue a, to identify a migratory and/or functional defect in the cd4+ treg cell population identified as expressing migratory and/or functional elements specific for target tissue a in any of tissue a, b or c, and whereby a combination of surface or intracellular markers on cd4+ treg cells is identified, which combination identifies which surface or intracellular markers should be present and which surface markers should not be present in cd4+ treg cell populations suitable for use as starting material in cellular immunotherapy.. .
Genovie Ab

Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics

This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against vsig1, ildr1, loc253012, ai216611, c1orf32 or fxyd3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages.
Compugen Ltd.

Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnology Gmbh



Immunotherapy topics:
  • Immunotherapy
  • Therapeutics
  • Antibodies
  • Immune Response
  • Monoclonal
  • Monoclonal Antibody
  • Stimulator
  • Immunostimulator
  • Compatibility
  • Histocompatibility
  • Specificity
  • Major Histocompatibility Complex
  • Radiation Therapy
  • Treatments
  • Amino Acid


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Immunotherapy for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Immunotherapy with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.4407

    file did exist - 2832

    2 - 1 - 57